SCHEMBL377173

SCHEMBL377173

CC(C)c1oc(-c2ccc(Cl)cc2Cl)nc1CCC(=O)c1ccccc1SC(=S)N(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.43
PPARA Q07869 5/20 0.43
PPARD Q03181 4/20 0.43
FURIN P09958 1/20 0.35
ALDH1A1 P00352 5/20 0.35
HPGD P15428 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 2/20 0.34
CNR1 P21554 2/20 0.33
TP53 P04637 1/20 0.33
LMNA P02545 1/20 0.32
ITGB2 P05107 1/20 0.32
ICAM1 P05362 1/20 0.32
ITGAL P20701 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377172 0.85 PPARG (0.44) PPARGPPARAPPARDFURINALDH1A1
SCHEMBL376966 0.84 PPARG (0.46) PPARGPPARAPPARDFURINALDH1A1
SCHEMBL3524999 0.78 PPARG (0.47) PPARGPPARAPPARDFURINALDH1A1
SCHEMBL376965 0.77 PPARG (0.49) PPARGPPARAPPARDFURINALDH1A1
SCHEMBL376949 0.76 PPARG (0.51) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL13296176 0.75 PPARG (0.52) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL2464485 0.75 PPARG (0.51) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL376648 0.74 PPARG (0.49) PPARGPPARAPPARDFURINALDH1A1
SCHEMBL2460888 0.73 PPARG (0.52) PPARGPPARAPPARDHPGDSMN1; SMN2
SCHEMBL4755248 0.72 PPARG (0.50) PPARGPPARAPPARDALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA PPARG 2/4885PPARA 3/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.